SerinaHUNTSVILLE, Ala. — Serina Therapeutics today announced the appointment of Randall Moreadith, M.D., Ph.D., as chief executive officer. Dr. Moreadith will lead the company’s business and financial strategy and will also oversee drug development, including clinical and regulatory strategies.

“We are delighted to have Randall on board,” said Milton Harris, president and chairman of the board. “Randall has an impressive track record of accomplishments. His experience and leadership will allow us to rapidly build our company.”

Prior to joining Serina Therapeutics, Moreadith, 56, was chief development officer at Nektar Therapeutics where he built a world-class clinical and drug development program. That program successfully moved several of the company’s PEGylated small molecule drugs into the clinic.

“I am excited to join Serina, a company with great potential to develop an exciting new polymer delivery technology,” said Moreadith. “I look forward to building Serina into a leader in polymer drug delivery and advancing our proprietary molecules in the clinic to treat difficult diseases such as cancer.”

Formerly the executive vice president and chief medical officer of Cardium Therapeutics, Moreadith led the advancement of novel DNA-based therapeutics into phase 2b and phase 3 late-stage development.  He also served as chief medical officer of Renovis, Inc. where he headed the clinical, regulatory and quality assurance groups.

Moreadith was co-founder, president and chief operating officer of ThromboGenics Ltd., a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development. Moreadith began his career in the pharmaceutical industry as principal medical officer of Quintiles, Inc., the world’s leading pharmaceutical services organization, where he led the cardiovascular therapeutics group.

An inventor on four patents, Moreadith has published more than 50 scientific papers and multiple book chapters, and has received numerous awards.  As a member of the faculty of the University of Texas Southwestern Medical Center, Moreadith was an established investigator of the American Heart Association.

He received his Ph.D. from Johns Hopkins University and his M.D. from Duke University. Following a fellowship in cardiology at Duke, he joined the laboratory of Dr. Philip Leder and was a Howard Hughes Medical Institute fellow in genetics at Harvard Medical School. Moreadith is also trained clinically in internal medicine.

Media Contact: Tacey Viegas
tviegas@serinatherapeutics.com
256-327-0443

About SerinaSerina Therapeutics, located in the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., is a drug delivery company that develops novel drug molecules with its polyoxazoline platform. The company’s technology is designed to provide a safer and more efficacious way to address a number of unmet medical needs. Serina’s founders were the principal officers of Shearwater Polymers, a drug delivery company that has seen wide success with polyethylene glycol technology.

 

Huntsville, Ala. — Serina Therapeutics today announced the appointment of Randall Moreadith, M.D., Ph.D., as chief executive officer.   Dr. Moreadith will lead the company’s business and financial strategy and will also oversee drug development, including clinical and regulatory strategies.

"We are delighted to have Randall on board," said Milton Harris, president and chairman of the board.   "Randall has an impressive track record of accomplishments. His experience and leadership will allow us to rapidly build our company."

Prior to joining Serina Therapeutics, Moreadith, 56, was chief development officer at Nektar Therapeutics where he built a world-class clinical and drug development program.   That program successfully moved several of the company’s PEGylated small molecule drugs into the clinic. 

"I am excited to join Serina, a company with great potential to develop an exciting new polymer delivery technology," said Moreadith. "I look forward to building Serina into a leader in polymer drug delivery and advancing our proprietary molecules in the clinic to treat difficult diseases such as cancer.” 

Formerly the executive vice president and chief medical officer of Cardium Therapeutics, Moreadith led the advancement of novel DNA-based therapeutics into phase 2b and phase 3 late-stage development.  He also served as chief medical officer of Renovis, Inc. where he headed the clinical, regulatory and quality assurance groups.

Moreadith was co-founder, president and chief operating officer of ThromboGenics Ltd., a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development. Moreadith began his career in the pharmaceutical industry as principal medical officer of Quintiles, Inc., the world’s leading pharmaceutical services organization, where he led the cardiovascular therapeutics group.

An inventor on four patents, Moreadith has published more than 50 scientific papers and multiple book chapters, and has received numerous awards.  As a member of the faculty of the University of Texas Southwestern Medical Center, Moreadith was an established investigator of the American Heart Association.

He received his Ph.D. from Johns Hopkins University and his M.D. from Duke University. Following a fellowship in cardiology at Duke, he joined the laboratory of Dr. Philip Leder and was a Howard Hughes Medical Institute fellow in genetics at Harvard Medical School. Moreadith is also trained clinically in internal medicine.
 

Contact Email:

tviegas@serinatherapeutics.com

Organization Background:

Serina Therapeutics, located in the HudsonAlpha Institute for Biotechnology in Huntsville, Ala., is a drug delivery company that develops novel drug molecules with its polyoxazoline platform. The company’s technology is designed to provide a safer and more efficacious way to address a number of unmet medical needs. Serina’s founders were the principal officers of Shearwater Polymers, a drug delivery company that has seen wide success with polyethylene glycol technology.

File Attachment:

serina_appoints_ceo.pdf